Genome-based development and clinical evaluation of a customized LAMP panel to rapidly detect, quantify, and determine antibiotic sensitivity of Escherichia coli in native urine samples from urological patients

• DOI: 10.1007/s10096-024-05030-3
• Publication Date: 2025-01-07T11:53:26Z
• Authors: Moritz Fritzenwanker; Marcel O. Grabitz; Vera Negwer; Oliver Schwengers; Borros Arneth; Trinad Chakraborty; Can Imirzalioglu; Florian Wagenlehner
• Keywords: Cefuroxime; Antimicrobial Stewardship; Point of care; Sulbactam; Trimethoprim

Abstract Purpose We designed and tested a point of care test panel to detect E.coli antibiotic susceptibility in urine samples from patients at the urological department. The aim this approach is facilitate choosing an appropriate for urinary tract infections (UTI) first presentation context increasing resistance uropathogens worldwide. Methods analyzed 162 isolates university department determine phenotypic genotypic data. With data we created customized LAMP (loop-mediated isothermal amplification) panels commercial machine with which possibly quantify six determinants. In second step these panel(s) diagnostic accuracy on 1596 compared routine microbiological culture. Results was detected 95.4% sensitivity 96.1% specificity. Dynamics amplification could be used gauge bacterial loads samples. Antibiotic good negative (sensitive) predictive values: ampicillin 92.8%, ampicillin/sulbactam 96.4%, cefuroxime cefotaxime 97.8%, trimethoprim/sulfamethoxazole 96.5%, ciprofloxacin 96.8%. Conclusion provided detection information within one hour thus principally guide initial therapy upon presenting UTI. helps select adequate as well providing stewardship. Follow up investigations will expand system other uropathogens.